Altimmune Inc
NASDAQ:ALT

Watchlist Manager
Altimmune Inc Logo
Altimmune Inc
NASDAQ:ALT
Watchlist
Price: 5.0145 USD -1.09%
Market Cap: 386.2m USD

During the last 3 months Altimmune Inc insiders bought 57.8k USD , and have not sold any shares. The stock price has dropped by 28% over this period (open performance analysis).

The last transaction was made on Mar 17, 2025 by Sohn Catherine A. (Director) , who bought 5.8k USD worth of ALT shares.

Last Transactions:
Sohn Catherine A.
Director
$+5.8k
Weaver Gregory L
Chief Financial Officer
$+52k
Drutz David
Director
$-54.2k
Drutz David
Director
$+862.5
Eisenstadt Richard I
Independent Director
$+43.1k
Harris Matthew Scott
Chief Financial Officer
$+42.2k
Drutz David
Director
$+38.4k
Pisano Wayne
Chairman of the Board
$-300.3k
Garg Vipin K
Chief Financial Officer (CFO)
$-400.3k
Garg Vipin K
Chief Financial Officer (CFO)
$-225.9k
Gill John
Chief Scientific Officer
$-40.7k
Roberts M Scot
Chief Executive Officer
$-323.8k
Roberts M Scot
Chief Executive Officer
$-65.5k
Jorkasky Diane
Chief Medical Officer
$-206.9k
Roberts M Scot
Chief Executive Officer
$-448.3k
Drutz David
Director
$+8k
Drutz David
Director
$+5.4k
Harris Matthew Scott
Chief Financial Officer
$-225.6k
Hodges Philip
Chief Operating Officer
$-96.5k
Schafer Klaus
Chief Operating Officer
$+24k
Hodges Philip
Chief Operating Officer
$-30k
Gill John
Chief Scientific Officer
$-100.4k
Pisano Wayne
Chairman of the Board
$-102.5k
Schafer Klaus
Chief Operating Officer
$-100.6k
Harris Matthew Scott
Chief Financial Officer
$-40.2k
Venrock Healthcare Capital Partners Iii, L.p.
$+11.3m
Shah Nimish P
Chief Financial Officer
$+2.7m
Velocity Pharmaceutical Holdings Llc
$-814.7k
Garg Vipin K
Chief Financial Officer (CFO)
$+42k
Pisano Wayne
Chairman of the Board
$+9.2k
Enright William
Chief Executive Officer
$+21.8
Sayare Mitchel
Executive Director of Program Management
$+332.1
View All Transactions

During the last 3 months Altimmune Inc insiders bought 57.8k USD , and have not sold any shares. The stock price has dropped by 28% over this period (open performance analysis).

The last transaction was made on Mar 17, 2025 by Sohn Catherine A. (Director) , who bought 5.8k USD worth of ALT shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
54.2k USD
1
9-12
months
0 USD
0
Bought
0-3
months
2
57.8k USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
0
0 USD
9-12
months
No Insider Transactions
0
0 USD

Altimmune Inc
Insider Trading Chart

Altimmune Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Altimmune Inc
Last Insider Transactions

Global
Insiders Monitor

Altimmune Inc
Glance View

Market Cap
362.8m USD
Industry
Biotechnology

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on peptide-based therapeutics for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 47 full-time employees. The company went IPO on 2005-10-06. The Company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH). The company is also developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B. The firm has initiated a Phase II clinical trial of HepTcell and are in Phase II and Phase I clinical development with pemvidutide for multiple indications. The company is conducting its Phase II clinical trial of HepTcell in the United States, United Kingdom, Canada, Germany and Spain, and conducting Its pemvidutide Phase I clinical trial in Australia. Its wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

ALT Intrinsic Value
5.1595 USD
Undervaluation 3%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top